Skip to main content
. 2023 May 25;7(15):4089–4101. doi: 10.1182/bloodadvances.2022009517

Table 1.

Patient characteristics

Treatment-naive, number or median (% or range) On ibrutinib, number or median (% or range) On acalabrutinib, number or median (% or range) Progressing, number or median (% or range)
Age 59 (48-77) 67 (53-78) 61 (50-74) 64 (39-76)
Sex
 Female 10 (50%) 6 (50%) 6 (40%) 0 (0%)
 Male 10 (50%) 6 (50%) 9 (60%) 10 (100%)
Prior therapy
 No 20 (100%) 6 (60%) 5 (33%) 8 (80%)
 Yes 0 (0%) 4 (40%) 10 (67%) 2 (20%)
IGHV
 Mutated 8 (40%) 5 (42%) 5 (33%) 0 (0%)
 Unmutated 10 (50%) 5 (42%) 10 (67%) 10 (100%)
 Missing 2 (10%) 2 (16%) 0 (0%) 0 (0%)
FISH
 del 17p 2 (10%) 4 (33%) 1 (7%) 6 (60%)
Absolute lymphocyte count 110 (10-328) 37 (5-317) 31 (4-146) 12 (6-31)
T-cell–to–CLL cell ratio 0.03 (0.01-0.08) 0.5 (0.01-0.40) 0.1 (0.01-0.56) 0.40 (0.08-0.69)
Time on BTKi therapy (mo) - 9 (5.5-57) 6 (5.2-48) 50 (15-72)

All characteristics given apply to the time of sample collection for the study.

Patients treated with ibrutinib (n = 19) or acalabrutinib (n = 18) had completed at least 6 cycles, and 10 (37%) had completed at least 12 cycles.

Among patients with disease progression, 7 (70%) were treated with ibrutinib and 3 (30%) with acalabrutinib.

FISH, florescence in situ hybrization; IGHV, immunoglobulin heavy-chain variable region mutational status.